DelMar Pharmaceuticals (NASDAQ: DMPI) and Javelin Mortgage Investment Corp (NYSE:JMI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Insider and Institutional Ownership

8.6% of DelMar Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for DelMar Pharmaceuticals and Javelin Mortgage Investment Corp, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DelMar Pharmaceuticals 0 1 3 0 2.75
Javelin Mortgage Investment Corp 0 0 0 0 N/A

DelMar Pharmaceuticals presently has a consensus target price of $13.00, suggesting a potential upside of 1,394.25%. Given DelMar Pharmaceuticals’ higher probable upside, analysts plainly believe DelMar Pharmaceuticals is more favorable than Javelin Mortgage Investment Corp.

Risk and Volatility

DelMar Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Javelin Mortgage Investment Corp has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.

Valuation & Earnings

This table compares DelMar Pharmaceuticals and Javelin Mortgage Investment Corp’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
DelMar Pharmaceuticals N/A N/A -$8.08 million ($0.74) -1.18
Javelin Mortgage Investment Corp N/A N/A N/A ($0.03) -239.33

Javelin Mortgage Investment Corp is trading at a lower price-to-earnings ratio than DelMar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DelMar Pharmaceuticals and Javelin Mortgage Investment Corp’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DelMar Pharmaceuticals N/A N/A -171.21%
Javelin Mortgage Investment Corp 59.64% 17.94% 2.30%

Summary

Javelin Mortgage Investment Corp beats DelMar Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Javelin Mortgage Investment Corp Company Profile

JAVELIN Mortgage Investment Corp. is a real estate investment trust (REIT). The Company invests primarily in fixed rate and hybrid adjustable rate mortgage backed securities. The Company may invest in collateralized commercial mortgage backed securities and other mortgage related investments, including mortgage loans, mortgage related derivatives and mortgage servicing rights. It invests in unsecured notes and bonds issued by government sponsored enterprises (GSEs), the United States Treasuries and money market instruments. The Company is managed by ARMOUR Capital Management LP.

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.